3D Medicines Inc., an innovative commercial-stage biopharmaceutical company, reported its financial results for the six months ended June 30, 2025. The company recorded a total comprehensive loss of RMB92.6 million, showing an improvement from the RMB114.1 million loss reported in the same period in 2024. This improvement came about despite increased share-based payment expenses, which were RMB20.5 million compared to RMB16.4 million in the previous year. The adjusted total comprehensive loss for the period was RMB72.2 million, down from RMB97.7 million in 2024. Revenue for the period saw a slight increase of 1.3%, rising to RMB209.2 million from RMB206.4 million in the prior year. This revenue was primarily generated from the sales of the commercialized product 恩維達® (Envafolimab, a subcutaneously-injectable PD-L1 inhibitor) to distributors. On the expense side, research and development expenses slightly decreased to RMB83.1 million from RMB85.3 million, while administrative expenses saw a notable reduction to RMB29.7 million from RMB43.5 million. However, selling and marketing expenses increased marginally to RMB111.5 million from RMB110.1 million. 3D Medicines Inc. continues to focus on independent research and development, aiming to advance their innovative cancer drug pipelines, which include globally leading or clinically valuable drug candidates. The company remains committed to maximizing cost-effectiveness and ensuring tangible outcomes from its investments.